About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Endostar First-line Treatment of Advanced NSCLC | Clinical Trials | Clareo Health

UNKNOWNPhase 2

Endostar First-line Treatment of Advanced NSCLC

The Efficacy and Safety of Continuous Administration of Endostar Combined With Chemotherapy for Patients With Advanced no Small Cell Lung Cancer: An Open-label, no Randomized Controlled Multicenter Phase II Study

NCT03123445•China Medical University, China

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Non Small Cell Lung Cancer

Interventions

Endostar

Gemcitabine

+1 more

Key Dates

Start Date

April 1, 2017

Primary Completion Date

April 1, 2019

Completion Date

September 1, 2019

Last Updated

April 21, 2017

Related Studies

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

RECRUITINGPhase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

RECRUITINGPhase 1/2

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132

Advanced Solid TumorNon Small Cell Lung Cancer+2 more

RECRUITINGPhase 3

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

NCT06284317

Non Small Cell Lung Cancer

RECRUITINGPhase 2

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

NCT06731413

Non-Small Cell Lung CancerNSCLC+2 more

RECRUITINGPhase 3

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369

Non Squamous Non Small Cell Lung Cancer

View all related studies

Contacts

liu yunpeng, PhD

CONTACT

00862483282312 cmu_trial@163.com

jin bo, PhD

CONTACT

00862483282542 jb_cmu@126.com

Sponsors

Lead Sponsor

China Medical University, China

Collaborators

The First Affiliated Hospital of Dalian Medical University
The Second Affiliated Hospital of Dalian Medical University
Liaoning Cancer Hospital & Institute
Shengjing Hospital
General Hospital of Shenyang Military Region

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 21, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions